207 related articles for article (PubMed ID: 18651858)
21. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
Lalezari JP; Ward DJ; Tomkins SA; Garges HP
J Antimicrob Chemother; 2007 Jul; 60(1):170-4. PubMed ID: 17491001
[TBL] [Abstract][Full Text] [Related]
22. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
23. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
27. Intermittent antiretroviral therapy in patients with controlled HIV infection.
Marchou B; Tangre P; Charreau I; Izopet J; Girard PM; May T; Ragnaud JM; Aboulker JP; Molina JM;
AIDS; 2007 Feb; 21(4):457-66. PubMed ID: 17301564
[TBL] [Abstract][Full Text] [Related]
28. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
30. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
[TBL] [Abstract][Full Text] [Related]
31. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
[TBL] [Abstract][Full Text] [Related]
32. Short-term efficacy and safety of stavudine in pretreated HIV-infected patients.
Villalba N; Soriano V; Gómez-Cano M; Castilla J; Mas A; González-Lahoz J
Antivir Ther; 1997 Jul; 2(3):185-9. PubMed ID: 11322273
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
Kline MW; Dunkle LM; Church JA; Goldsmith JC; Harris AT; Federici ME; Schultze ME; Woods L; Loewen DF; Kaul S
Pediatrics; 1995 Aug; 96(2 Pt 1):247-52. PubMed ID: 7630678
[TBL] [Abstract][Full Text] [Related]
34. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
J Infect Dis; 2007 Dec; 196(12):1773-8. PubMed ID: 18190257
[TBL] [Abstract][Full Text] [Related]
35. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
[TBL] [Abstract][Full Text] [Related]
37. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF
HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
Durier C; Capitant C; Lascaux AS; Goujard C; Oksenhendler E; Poizot-Martin I; Viard JP; Weiss L; Netzer E; Delfraissy JF; Aboulker JP; Lévy Y
AIDS; 2007 Sep; 21(14):1887-97. PubMed ID: 17721096
[TBL] [Abstract][Full Text] [Related]
39. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.
Hernández-Novoa B; Antela A; Gutiérrez C; Pérez-Molina JA; Pérez-Elías MJ; Dronda F; Moreno A; Casado JL; Page C; Pumares M; Galán JC; Moreno S
HIV Med; 2008 Apr; 9(4):187-91. PubMed ID: 18298579
[TBL] [Abstract][Full Text] [Related]
40. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
